Pfizer’s vaccine against respiratory syncytial virus, or RSV, showed promising results protecting newborns when the shot is administered to mothers during the late stages of their pregnancies, according to new clinical trial data from the company.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.